Drugs.com - New Drug Approvals

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis...

Apr 30, 2025 - 22:55
 0
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis...
Read More

Tags:

Previous Article

Premier Completes the Conversion and Historic Conservation of Le Pavillon New Or...

Next Article

FDA Approves Imaavy (nipocalimab-aahu) for the Treatment of Generalized Myasthen...

Related Posts

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefilled Syringe for Self-Injection

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefil...

Apr 26, 2025  0

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to Xgeva

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to...

Apr 26, 2025  0

FDA Approves Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for Prostate Cancer Imaging

FDA Approves Gozellix (kit for the preparation of galli...

Apr 26, 2025  0